SCHEMBL8047356

SCHEMBL8047356

COc1ccn2ncc(-c3nc4[nH]nc(N5CCN(C)CC5)c4cc3F)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 1/20 0.38
HRH4 Q9H3N8 4/20 0.38
PDE2A O00408 1/20 0.37
HTR2C P28335 2/20 0.37
HTR2A P28223 1/20 0.37
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
DYRK1A Q13627 1/20 0.36
FGFR1 P11362 1/20 0.35
KDR P35968 1/20 0.35
AURKA O14965 2/20 0.35
LRRK2 Q5S007 1/20 0.35
ACVR1 Q04771 2/20 0.35
USP2 O75604 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8049607 0.92 PDE2A (0.39) PDE2ADYRK1AMAPK1MEN1KMT2A
SCHEMBL8046001 0.85 JAK2 (0.42) HRH4CLK2CLK3DYRK1AACVR1
SCHEMBL3243059 0.84 PRMT5 (0.36) PDE2AHTR2CHTR2AMEN1KMT2A
SCHEMBL8042722 0.82 FGFR1 (0.43) HTR2AFGFR1KDR
SCHEMBL8054838 0.81 PIK3CA (0.36) PDE2ADYRK1AMAPK1PIM1
SCHEMBL8043906 0.79 PRMT5 (0.35) PDE2AHTR2CHTR2AMAPK1
SCHEMBL8043913 0.78 PIK3CA (0.36) HTR2CHTR2AMEN1KMT2A
SCHEMBL8041870 0.78 PIK3CA (0.34) HTR2CHTR2ADYRK1APIM1
SCHEMBL3228319 0.77 TGFBR2 (0.37) PDE2AMAPK1PIM1
SCHEMBL13099765 0.77 EGFR (0.37) MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
WO-2009038385-A2 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME MAP3K20, MAP3K3, MAP3K1 MAP4K1 44/4885HRH4 2076/4885PDE2A 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.